MPs have heard that contact with a bacterial toxin during early childhood could be a chief factor behind the rise of bowel cancer among those under 50.
A toxin called colibactin, produced by some strains of E. coli in the gut, emerged as a leading suspect in the rise of bowel cancer among those under 50, when an Oxford researcher told UK lawmakers that known risk factors explain only about half of the cases doctors diagnose.
Dr Karl Smith-Byrne, a senior molecular epidemiologist in the cancer epidemiology unit at the University of Oxford, told the Commons science and technology committee that obesity, smoking, alcohol and inactivity account for roughly half of colorectal cancers.
He went further on obesity alone, telling the committee: “If we just take obesity, the amount that that may explain among total colorectal cancer might be about 10 per cent and so I would not think it is plausible that all of the rise in early onset can be explained by overweight and obesity or things that we’re aware of.”

Cases of early-onset bowel cancer have doubled in many countries over the past two decades. The disease remains far more common in the over-50s, but global figures show diagnoses rising steeply in younger people. Globally, bowel cancer ranks as the world’s third most frequently diagnosed cancer and makes up roughly one in 10 of all cases.
Last year scientists identified colibactin, made by some variants of E. coli that normally live harmlessly in the gut, as a potential driver of early-onset colorectal cancer. Tumours taken from patients under 40 carried the toxin’s signature mutations at triple the rate seen in tumours from people over 70. Smith-Byrne cautioned that much remains unknown, saying “we do not know how much of cancer can be explained by that,” but told MPs: “That’s probably the leading explanation at the moment.”
He said early-life damage could set the disease in motion: “If it is causing mutations, it’s causing mutations at a sensitive period earlier in life, and that can give that person’s colon or their rectum a head start on its journey towards being cancerous or developing these tumours.” Smith-Byrne is himself a survivor of early-onset rectal cancer.
Prof Mike Stratton of the Sanger Institute, who did not attend the hearing, has said that colibactin induces mutations in certain children but not in others, and that evidence of these mutations can be traced back to infancy. By the age of 10, affected children can carry a similar “mutational burden” to a 50-year-old, his work showed.
Prof Helen Coleman, a cancer epidemiologist at Queen’s University Belfast, told MPs colibactin was “the first new clue that we’ve had in quite some time,” but that its role was still under investigation.
“It could be something you were exposed to in very early childhood, possibly even in the prenatal period, and that makes it very difficult to study,” she said, adding: “But I can assure the committee there’s lots of teams around the UK, including our own, who are really deeply invested in trying to better understand this.”
According to The Sun, Coleman also told the committee that across the population about one in 10 bowel cancer cases is “probably inherited”, rising to one in five among people under 50.
Some suspect that particular E. coli variants evolved in recent decades to produce colibactin, a possibility Prof Elio Riboli, a cancer epidemiologist at Imperial College London, raised at the hearing. “This colibactin is essentially found in people born after 1960. Something has happened in the E coli bacteria … There must have been a mutation, and there is a new bacteria,” he told the committee.
“The quick win could come from applying what we know,” he said. “We could prevent about 60% of the cancers occurring now, but we are not applying in society what we know.”
Whether colibactin actually drives bowel cancer remains unanswered, but it is a question scientists are now actively pursuing.